ph11

PH11 is a novel Focal Adhesion Kinase (FAK) inhibitor. PH11 restores TRAIL apoptotic pathway in PANC-1 cells through down-regulation of c-FLIP via inhibition of FAK and the phosphatidylinositol-3 kinase (PI3K)/AKT pathways. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) emerges as one of the most-promising experimental cancer therapeutic drugs and is currently being tested in clinical trials. However, both intrinsic and acquired resistance of human cancer cells to TRAIL-induced apoptosis poses a huge problem in establishing clinically efficient TRAIL therapies.

VS-II-173 is a novel potent Pim1 and Pim3 inhibitor, selectively inducing AML cell death.

SI-2 hydrochloride (EPH 116 hydrochloride) is a highly promising inhibitor of SRC-3 SMI: SRC-3 (PPI)(IC50 values of 3-20 nM for breast cancer cell death), with acceptable oral availability.

Phosphostim, a gamma9deta2 T lymphocytes agonist, is used potentially for the treatment of renal cell carcinoma, HCV infection.

Azodicarbonamide is the first nucleocapsid inhibitor known to inhibit HIV-1 and various retroviruses by targeting the nucleocapsid CCHC domains. In a standard cellular antiviral assay, the compound inhibited HIV-1RF-induced CEM-SS cytopathy with an EC50 value of 38 µM.